Group 1 - AstraZeneca PLC (NASDAQ:AZN) is highlighted in Jim Cramer's game plan, indicating strong interest in the stock as part of a heavy earnings rotation alongside other major companies [1] - The company manufactures prescription medicines across various therapeutic areas, including oncology, cardiovascular, respiratory, and rare diseases [3] - Cramer expressed a positive outlook on AstraZeneca's cancer franchise, suggesting that it is stronger than previously anticipated, and recommended holding onto the stock over AbbVie [3] Group 2 - There is a recognition of AstraZeneca's potential as an investment, but some analysts believe that certain AI stocks may offer greater upside potential with less downside risk [4]

Company Overview - Encompass Health Corporation is the largest owner and operator of inpatient rehabilitation hospitals in the U.S., with approximately 166 facilities across 38 states [3] - The company provides intensive post-acute care, including physical, occupational, respiratory, and speech therapy for patients recovering from major illnesses and injuries [3] Allegations of Wrongdoing - An article published by The New York Times on July 15, 2025, raised patient safety concerns at Encompass rehabilitation hospitals, stating that the company owns 34 of the 41 inpatient rehab facilities flagged by Medicare for having "statistically significantly worse rates of potentially preventable readmissions" [4] - Specific incidents mentioned include fatal carbon monoxide poisoning, medication errors, and bed alarm failures [4] Market Reaction - Following the publication of the article, Encompass's stock price fell by $12.39 per share, or 10.35%, closing at $107.28 per share on July 15, 2025 [5]